Atypical chronic myeloid leukemia following organ transplants

Clinical Transplantation

Volumn 22, Issue 2, 2008, Pages 258-261

  Fontana, V ^a   Dudkiewicz, P ^a   Horstman, L L ^a   Tzakis, A G ^a   Ahn, Yeon S ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic myeloid leukemia; Immunosuppression; Malignancies; Organ transplant; Philadelphia chromosome; Tacrolimus

Indexed keywords

ANAGRELIDE; BCR ABL PROTEIN; HEMOGLOBIN; IMATINIB; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RECOMBINANT ERYTHROPOIETIN; TACROLIMUS;

ADULT; ANEMIA; ARTICLE; BLOOD TRANSFUSION; BONE MARROW BIOPSY; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; FEMALE; GRAFT REJECTION; HEPATITIS C; HUMAN; HUMAN TISSUE; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LEUKOCYTE COUNT; LIVER TRANSPLANTATION; MALE; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THROMBOCYTE COUNT;

EID: 41049108270     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2007.00775.x     Document Type: Article

References (24)

1. Cole WH. The increase in immunosuppression and its role in the development of malignant lesions. J Surg Oncol 1985: 30: 139.
2. Penn I. Cancers stimulating organ transplantation. N Engl J Med 1990: 323: 1767.
3. Buell JF, Gross TG, Woodle ES. Malignancy after transplantation. Transplantation 2005: 80: 254.
4. Sawyers CL, Shah NP. Chronic myeloid leukemia. In: H offman R, B enz EJ J r, S hattil SJ et.al. eds. Hematology. Chapter 69. Philadelphia: Elsevier Churchill Livingstone, 2005: 1247.
5. Mooy JMV, Hagenouw JCW, Lameijer-Taal LDF, Van Turnhout JM. Chronic granulocytic leukemia in a renal transplant recipient. Cancer 1977: 41: 7.
6. Shima T, Oku N, Goto H et al. Chronic myelomonocytic leukemia and esophageal cancer developed in a renal allograft recipient. Rinsho Ketsueki 1993: 34: 842.
7. Sanz L, Cervantes F, Esteve J et al. Chronic myeloid leukemia after renal transplantation: Report of a case and review of the bibliography. Sangre (Barc) 1996: 41: 391.
8. Fernandez-Aviles F, Ribera JM, Batle M, Lauzurica R. Chronic myeloid leukemia after kidney transplantation. Sangre (Barc) 1997: 52: 85.
9. Mignozzi M, Picca S. Chronic myelogenous leukemia following kidney transplantation in a pediatric patient. Pediatr Nephrol 2001: 16: 852.
10. P elloso LA, C ampos MG, N ascimento M, S ilva MR, P estana JO, C hauffaille M de L. Chronic myeloid leukemia following kidney transplantation. Leuk Res 2005: 29: 353.
11. Tremblay F, Fernandez M, Habbab F, de Edwardes MD, Loertscher R, Meterissan S. Malignancy after renal transplantation: Incidence and role of type of immunosuppression. J Surg Onc 2002: 9: 785.
12. V athsala A. Preventing renal transplant failure. Ann Acad Med Singapore 2005: 34: 36.
13. Nafar M, Einollahi B, Hemati K, Gholi FP, Firouzan A. Development of malignancy following living donor kidney transplantation. Transplant Proc 2005: 37: 3065.
14. Vajdic CM, Mc Donald SP, Mc Credie MR et al. Cancer incidence before and after kidney transplantation. JAMA 2006: 296: 2823.
15. Xiol X, Guardiola J, Menendez S et al. Risk factors for development of de novo neoplasia after liver transplantation. Liver Transpl 2001: 7: 971.
16. Saigal S, Norris S, Muiesan P, Rela M, Heaton N, O'Grady J. Evidence of differential risk for posttransplantation malignancy based on pretransplantation cause in patients undergoing liver transplantation. Liver Transpl 2002: 8: 482.
17. Williams R. 15th Seah Cheng Siang memorial Lecture: Liver transplantation-lessons learnt and future horizons. Ann Acad Med Singapore 2005: 34: 689.
18. Vallejo GH, Romero CJ, de Vicente JC. Incidence and risk factors for cancer after liver transplantation. Crit Rev Oncol Hematol 2005: 56: 87.
19. Gruber S, Matas AG. Etiology and pathogenesis of tumors occurring after organ transplantation. Transpl Sci 1994: 4: 87.
20. Kehinde EO, Petermann A, Morgan JD et al. Triple therapy and incidence of de novo cancer in renal transplant recipients. Br J Surg 1994: 81: 985.
21. Gruber SA, Gillingham K, Sothern RB, Stephanian E, Mata AJ, Dunn DL. De novo cancer in cyclosporine-treated and non-cyclosporine-treated adult primary renal allograft recipients. Clin Transplant 1994: 8: 388.
22. Sommerer C, Kostandin M, Dengler T et al. Pharmacodynamic monitoring of cyclosporine in a renal allograft shows a quantitative relationship between immunosuppression and the occurrence of recurrent infections and malignancies. Transplantation 2006: 82: 1280.
23. Oliviera VD, Zankl H, Rath Y. Mutagenic and cytotoxic effects of immunosuppressive drugs on human lymphocyte cultures. Exp Clin Transplant 2004: 2: 273.
24. Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BD. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005: 80: 883.